Expand CRDL Menu
CRDL MENU

CRDL Latest Press Releases

-- February 10, 2026 --

Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure Newsfile 7:27 AM

-- January 23, 2026 --

Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million Newsfile 9:16 AM

-- January 16, 2026 --

Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million Newsfile 8:46 AM
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million Newsfile 8:42 AM

-- January 13, 2026 --

Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis Newsfile 7:27 AM

-- December 1, 2025 --

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions Newsfile 7:27 AM

-- November 13, 2025 --

Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040 Newsfile 7:45 AM

-- November 5, 2025 --

Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases Newsfile 7:45 AM

-- October 21, 2025 --

Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027 Newsfile 7:27 AM

-- October 17, 2025 --

Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027 Newsfile 4:34 PM
Market Data Delayed 15 Minutes